精准检测！VENTANA PD-L1（SP142）非小细胞肺癌适应症获批上市( 三 ) *仅供医学专业人士阅读参考构

[6]Davis,AndrewA.,andVaibhavG.Patel.TheroleofPD-L1expressionasapredictivebiomarker:ananalysisofallUSFoodandDrugAdministration(FDA)approvalsofimmunecheckpointinhibitors.Journalforimmunotherapyofcancer7.1(2019):278.
[7]Prince,SpasenijaSavic,andLukasBubendorf.''PredictivepotentialandneedforstandardizationofPD-L1immunohistochemistry.''VirchowsArchiv474.4(2019):475-484.
[8]Tsao,MINGSOUND,etal.IASLCatlasofPD-L1immunohistochemistrytestinginlungcancer.Aurora,CO:InternationalAssociationfortheStudyofLungCancer(2017).
[9]Lawson,NicolaL.,etal.''Mappingthebindingsitesofantibodiesutilizedinprogrammedcelldeathligand-1predictiveimmunohistochemicalassaysforusewithimmuno-oncologytherapies.''ModernPathology33.4(2020):518-530.
[10]VENTANAPD-L1(SP142)Assay(CEIVD)PackageInsert.
[11]Herbst,etal.ESMOIO2019(AbsLBA1)
[12]http://app1.nmpa.gov.cn/data_nmpa/face3/base.jsp?tableId=26&tableName=TABLE26&title=%B9%FA%B2%FA%D2%BD%C1%C6%C6%F7%D0%B5%B2%FA%C6%B7%A3%A8%D7%A2%B2%E1%A3%A9&bcId=152904417281669781044048234789
[13]2018ESMOhandbookofimmune-oncology.
[14]VENTANAPD-L1(SP263)Assay(CEIVD)PackageInsert.
[15]https://fda.report/PMA/P160046
【精准检测！VENTANA PD-L1（SP142）非小细胞肺癌适应症获批上市】*此文仅用于向医学人士提供科学信息，不代表本平台观点

文章图片